Murphy Teresa, Kelly Meagan, Shimagaki Kai S, DeStefanis Thomas, Galeotos Gabriel, Lee Myungjin, Wei Qing, Novak Jan, Bar Katharine J, Barton John P, Lynch Rebecca M
bioRxiv. 2025 Jul 18:2025.07.15.664896. doi: 10.1101/2025.07.15.664896.
Broadly neutralizing antibodies (bNAbs) provide a useful tool for HIV cure strategies because of their ability to target conserved regions on the envelope (Env) protein in the context of both virions and infected cells. One of the most well studied bNAbs is the CD4 binding site (CD4bs) antibody, VRC01 and others in its class. A major obstacle to effective cure strategies with bNAbs is viral immune escape. A deeper understanding of escape pathways from VRC01-class antibodies in genetically diverse samples is needed. Using an viral escape assay where infected CD4 T cells were cultured in the presence of increasing VRC01 concentrations, complete resistance to VRC01 was detected in Env 246.F3 by day 42. We determined that resistance was due to a mutation at position N276 that resulted in elimination of the glycan-attachment site. As the loss of a glycan at this site is known to increase virus sensitivity to CD4bs antibodies, we explored this finding further. Specifically, we introduced N276D mutation into the 12-virus global Env panel and measured neutralization susceptibility to a panel of CD4bs bNAbs. This N276D mutation increased resistance or sensitivity depending on the Env and bNAb in question, emphasizing a dual role of glycan N276 in VRC01-class bNAb neutralization. The role of this glycan in escape was demonstrated to be dependent on the context of the Env, the bNAb and the glycosylation complexity of the virus due to producer cells. These findings underscore the complexity of glycosylation in genetically diverse HIV escape from antibodies.
Despite decades of research, an HIV cure remains elusive, largely due to the virus's immense genetic variability and ability to evade immune clearance. While antiretroviral therapy (ART) suppresses viral replication, it does not eradicate the virus and presents long-term challenges related to toxicity, access, and adherence. Broadly neutralizing antibodies (bNAbs), particularly those targeting the conserved CD4 binding site such as VRC01 and others in its class, offer promise for durable control or cure by targeting both circulating virus and infected cells. However, viral escape from bNAbs remains a critical hurdle. In this study, we demonstrate that glycan-mediated escape from VRC01-class bNAbs is highly context-dependent-shaped by Env, bNAb, and the glycosylation patterns introduced by the producer cell. These findings emphasize the dual role of glycans in affecting antibody sensitivity and underscore the importance of viral and host factors in shaping effective bNAb-based cure strategies across diverse HIV-1 strains.
广泛中和抗体(bNAbs)为艾滋病治愈策略提供了一种有用的工具,因为它们能够在病毒颗粒和受感染细胞的背景下靶向包膜(Env)蛋白上的保守区域。研究最深入的bNAbs之一是CD4结合位点(CD4bs)抗体VRC01及其同类抗体。使用bNAbs进行有效治愈策略的一个主要障碍是病毒免疫逃逸。需要更深入地了解基因多样化样本中VRC01类抗体的逃逸途径。在一项病毒逃逸试验中,将受感染的CD4 T细胞在不断增加的VRC01浓度下培养,到第42天时在Env 246.F3中检测到对VRC01的完全抗性。我们确定抗性是由于N276位的突变导致聚糖附着位点的消除。由于已知该位点聚糖的缺失会增加病毒对CD4bs抗体的敏感性,我们进一步探究了这一发现。具体而言,我们将N276D突变引入12种病毒的全球Env库中,并测量了对一组CD4bs bNAbs的中和敏感性。这种N276D突变根据所涉及的Env和bNAb增加或降低抗性,强调了聚糖N276在VRC01类bNAb中和中的双重作用。该聚糖在逃逸中的作用被证明取决于Env的背景、bNAb以及由于生产细胞导致的病毒糖基化复杂性。这些发现强调了基因多样化的HIV从抗体逃逸过程中糖基化的复杂性。
尽管经过数十年的研究,艾滋病的治愈仍然难以实现,这主要是由于病毒巨大的遗传变异性和逃避免疫清除的能力。虽然抗逆转录病毒疗法(ART)可抑制病毒复制,但它并不能根除病毒,并且带来了与毒性、可及性和依从性相关的长期挑战。广泛中和抗体(bNAbs),特别是那些靶向保守CD4结合位点的抗体,如VRC01及其同类抗体,通过靶向循环病毒和受感染细胞,为持久控制或治愈带来了希望。然而,病毒从bNAbs逃逸仍然是一个关键障碍。在这项研究中,我们证明聚糖介导的从VRC01类bNAbs逃逸高度依赖于背景,由Env、bNAb以及生产细胞引入的糖基化模式所塑造。这些发现强调了聚糖在影响抗体敏感性方面的双重作用,并强调了病毒和宿主因素在为不同HIV-1毒株制定有效的基于bNAb的治愈策略中的重要性。